Brickell Biotech Appoints Top Lilly Executive, Robert Brown, as Chief Executive Officer

Notable leadership change comes as Brickell prepares to progress its
lead product candidate, sofpironium bromide, to Phase 3 clinical trials
in primary axillary hyperhidrosis (excessive underarm sweating)

BOULDER, Colo.–(BUSINESS WIRE)–Brickell Biotech, Inc. (“Brickell”), a clinical-stage pharmaceutical
company focused on the development of innovative and differentiated
therapeutics for the treatment of skin diseases, today announced the
appointment of Robert Brown as Chief Executive Officer and Director,
effective January 1, 2019. Mr. Brown assumes the role from Reginald
Hardy, Brickell’s current CEO and co-founder, who initiated the
leadership succession plan to best position Brickell and its lead
product candidate, sofpironium bromide, as it progresses to Phase 3 in
the first half of 2019. Mr. Hardy will remain on Brickell’s Board of
Directors and will serve as special advisor to the CEO.

“Rob is the ideal candidate to assume the CEO role at this moment of
Brickell’s growth. I’m certain that his comprehensive pharmaceutical
industry experience will guide us confidently into the marketplace,”
said Mr. Hardy. “As sofpironium bromide moves into Phase 3 trials early
next year, it was the right time to strengthen our commercial
capabilities and to grow our sales and marketing infrastructure. I’m
excited for our next steps as a company and look forward to contributing
to our success as a member of the Board of Directors.”

Mr. Brown brings to Brickell more than 30 years of experience at
pharmaceutical industry giant Lilly where he currently serves as the
Chief Marketing Officer and Senior Vice President. During his years at
Lilly, Mr. Brown has helped bring many blockbuster products to market,
including Taltz®, Cialis® and Cymbalta®, as well as overseeing the
launch of seven new chemical entities (NCEs) across a wide range of
therapeutic categories, including dermatology. In addition to his
product commercialization expertise, Mr. Brown has significant
leadership experience. Among many positions, he served as President and
General Manager of Lilly’s China affiliate, Lilly Suzhou JV, growing the
affiliate from 45 employees to over 500, and in just three years
catapulting the company up 46 places in industry sales rankings.

“We are incredibly excited to have Rob join Brickell and are confident
that he will prove to be an invaluable asset to the company,” said
Brickell’s Board Chairman, Charlie Stiefel. “Rob has commercialized
numerous products – several of which achieved blockbuster status in the
marketplace, even as the second or third product coming to market within
its respective category. This is especially relevant experience as we
look to enter the hyperhidrosis market, an area of vast unmet medical
need that, until recently, had not seen any therapeutic advances for
years but is now becoming a better understood market opportunity.”

Mr. Brown received his Bachelor’s degree in Economics from DePauw
University and his Master of Business Administration in Marketing from
Indiana University. While at Lilly, Brown served as a Board Member of
Lilly ICOS LLC, and he currently serves as a Board Member at Franklin
College.

“I was very attracted by the opportunity to join such a promising and
well-positioned pre-commercial, late-stage company like Brickell, where
my pharmaceutical industry experience could have a real impact,” said
Mr. Brown. “This company has tremendous momentum and a pipeline of
exciting NCEs that are on track to progress rapidly. I’m particularly
excited about sofpironium bromide, which has the potential to be a
best-in-class product and to provide clinically meaningful therapeutic
relief to millions of Americans living with hyperhidrosis.”

Brickell is currently on track to initiate two Phase 3 pivotal trials
for sofpironium bromide in the first half of 2019, and by the second
half of 2020 the company intends to have completed all necessary
activities required to file a New Drug Application (NDA) with the FDA.
In addition, the company’s current pipeline consists of four new
molecular entities targeting the treatment of cutaneous T-cell lymphoma,
psoriasis, androgenic alopecia and allergic contact dermatitis, which
are in earlier stages of development.

About Sofpironium Bromide

Sofpironium bromide, a new chemical entity and “soft” drug, belongs to a
class of medications called anticholinergics. Anticholinergics block the
action of acetylcholine, a chemical that transmits signals within the
nervous system that are responsible for a range of bodily functions,
including the activation of sweat glands. Soft drugs, such as
sofpironium bromide, exert their action topically and are rapidly
metabolized once absorbed into the blood. This mechanism of action
allows for effective doses to be used while reducing the limiting
systemic side effects associated with other drugs in this class.

About Brickell Biotech

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company
focused on the development of innovative and differentiated therapeutics
for the treatment of skin diseases. Its pipeline consists of potential
novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma,
psoriasis, androgenic alopecia and allergic contact dermatitis.
Brickell’s management team and board of directors have extensive
experience in product development, having served in leadership roles at
several pharmaceutical and successful start-up companies. Its strategy
is to leverage this experience to in-license, acquire, develop and
commercialize products that Brickell believes can be successful in the
dermatology marketplace. For more information, visit www.brickellbio.com.

Contacts

Media
Elizabeth Kolln
646-805-2080
Elizabeth.kolln@finsbury.com

Sky Optics Media drone video